How to Get PRP Therapy Online in Portugal
PRP Therapy for weight loss is not approved in the EU. Instead, get a prescription for proven weight loss medications like Ozempic, Wegovy, or Mounjaro online in Portugal.
DIRECT ANSWER
An online consultation lets an EU-licensed doctor review your case and, if appropriate, issue a prescription that is valid across the EU.
Less than 4 hours on average
Prescription issued in less than 4 hours on average if approved.
EU-licensed doctors
Every case is reviewed by a licensed clinician.
Valid across the EU
Approved prescriptions can be used at any EU pharmacy.
In this article
If you are looking to get PRP Therapy online in Portugal for weight loss, it is important to know that this treatment is not currently approved for this use in the EU. Hi-Doctor does not offer PRP Therapy. However, you can access EU-approved, proven weight loss medications like Ozempic, Wegovy, or Mounjaro through an online consultation. An EU-licensed doctor reviews your case for just 25€, issuing a prescription within 24 hours if appropriate. You can then pick up your medication at any EU pharmacy, risk-free.
How it works — get your consultation in 4 steps
Accessing approved weight loss medication through Hi-Doctor is straightforward and secure. No waiting rooms, no video calls, just a simple online process:
- Complete a quick online questionnaire: Share details about your health, medical history, and weight loss goals. This takes just a few minutes.
- EU-licensed doctor reviews your case: An experienced, EU-licensed doctor individually assesses your information. They determine if a weight loss treatment is appropriate and safe for you.
- Receive a REMPE prescription in <24 hours if approved: If the doctor approves, you get a valid REMPE electronic prescription (Spain's official digital private prescription standard) as a downloadable PDF. This is accessible in your Hi-Doctor account and sent via email. The online consultation costs 25€. If the doctor determines the treatment is NOT appropriate, your fee is refunded — you pay nothing.
- Present your prescription at any EU pharmacy: Print your PDF prescription or show it on your phone at any pharmacy in any EU country. This is possible thanks to EU Directive 2011/24/EU. Pharmacists retain the right to refuse to dispense.
Who qualifies
You may qualify for prescription weight loss medication if you meet specific medical criteria. This typically involves a Body Mass Index (BMI) above a certain threshold or a lower BMI with weight-related health conditions. An EU-licensed doctor assesses your full medical history and current health status through the online questionnaire to determine eligibility. Conditions that generally preclude prescription include certain heart conditions, kidney disease, or a history of pancreatitis.
What the medication actually does
EU-approved weight loss medications, such as GLP-1 receptor agonists like Ozempic, Wegovy, Saxenda, and the dual GIP/GLP-1 agonist Mounjaro, work by mimicking natural hormones that regulate appetite and blood sugar. They help you feel fuller for longer, reduce cravings, and can lead to significant and sustainable weight loss when combined with lifestyle changes. These medications have undergone rigorous clinical trials and are proven effective for chronic weight management.
In clinical trials, patients on GLP-1 agonists have shown an average weight loss of 15-20% of their initial body weight. (Source: Clinical trial data for specific GLP-1 agonists)
Side effects and when to stop
Common side effects of these medications can include nausea, vomiting, diarrhea, or constipation, especially when first starting treatment. These usually subside as your body adjusts. Serious side effects are rare but can include pancreatitis or gallbladder issues. It is crucial to follow your doctor's instructions carefully. Contact your doctor immediately if you experience severe abdominal pain, persistent vomiting, or symptoms of an allergic reaction. The doctor advises you on when to stop treatment based on your progress and any adverse effects.
Key Takeaways
- PRP Therapy for weight loss is not EU-approved and not offered by Hi-Doctor.
- Access EU-approved weight loss medications like Ozempic or Wegovy via online consultation.
- Consultation costs 25€ with a money-back guarantee if treatment is unsuitable.
- Receive a valid REMPE prescription in under 24 hours, if approved.
- Use your prescription at any EU pharmacy, recognizing pharmacists' right to refuse.
Why Hi-Doctor vs. walking into a clinic
Choosing Hi-Doctor offers distinct advantages over traditional clinic visits, especially for busy individuals or those seeking privacy and convenience:
- Online convenience: Complete your consultation from anywhere, anytime, without appointments or waiting rooms.
- EU-licensed doctors: Your case is reviewed by qualified, EU-licensed medical professionals, ensuring high standards of care.
- Money-back guarantee: Pay 25€ for the consultation. If the doctor determines the treatment isn't appropriate, your money is fully refunded. No risk.
- Fast prescription: Receive your valid REMPE electronic prescription in under 24 hours if approved.
- EU-wide recognition: Your prescription is designed for EU-wide recognition under Directive 2011/24/EU.
- Private and secure: Your data is handled with privacy and security.
- Proven track record: Over 50,000 patients served with a 4.8 Trustpilot rating.
| Feature | Hi-Doctor Online Consultation | Traditional Clinic Visit |
|---|---|---|
| Cost | 25€ (money-back guarantee) | Varies, often higher |
| Prescription Time | <24 hours (if approved) | Requires in-person visit |
| Convenience | Anywhere, anytime online | Requires travel and appointments |
| Privacy | Secure online process | Less private, waiting rooms |
| EU-wide Prescription | Yes, REMPE standard | Often limited to local country |
COMMON QUESTIONS
Frequently asked questions
No, PRP Therapy for weight loss is not approved by the European Medicines Agency (EMA) and is therefore not legally available for prescription or purchase online in Portugal or anywhere in the EU.
